This paper assesses the global economic implications of the proposed strict documentation requirements on traded shipments of potentially genetically modified (GM) commodities under the Cartagena Protocol on Biosafety.

The financial mechanism of the Convention on Biological Diversity (CBD), operated by the GEF, has assisted eligible countries to implement their commitments for achieving the objectives of this unique international legal instrument. Considering that most of the biological diversity is located in developing countries, the importance of the GEF to the CBD remains fundamental. This publication highlights the achievements of the GEF since its inception, summarizes its current investment strategy, and begins to map the way forward for the next phase of the GEF.